close
close

Fighting diseases with antibody-drug conjugates

In this podcast episode entitled “Fighting disease with antibody-drug conjugates”we will examine the key considerations when selecting an antibody for use in antibody-drug conjugates (ADCs). We will also discuss the preclinical models used to evaluate the pharmacokinetics and pharmacodynamics of ADCs.

This conversation offers Dr Philipp SpycherCSO and co-founder of Araris Biotech, and Dr Rebecca BoohakerDirector of Oncology at Southern Research.

This podcast is produced in partnership with Molecular Devices. Molecular Devices' innovative life science technology enables scientific breakthroughs for customers in academia, pharmaceuticals, government and biotechnology. For more information, visit moleculardevices.com.

About the speakers

Dr. Philipp Spycher, CSO and co-founder of Araris Biotech

Philipp SpycherAs the inventor of the Araris ADC technology, Philipp has an extensive background in bioconjugation and ADCs. He was the founding CEO of Araris since its inception in 2019, securing $40 million in funding from Swiss, UK, US and Korean investors and $2.5 million in non-dilutive funding from the Swiss Accelerator Grant (funding rate of five percent). He positioned Araris to be a paradigm shift in the development of targeted cancer therapies and has been its CSO since October 2023.

During his postdoctoral work at PSI, he introduced the novel transglutaminase approach for antibody conjugation, which led to the discovery of the Araris ADC technology. He obtained his Master's degree and PhD from ETH Zurich at the interface between materials science and protein engineering.

Dr. Rebecca Boohaker, Director of Oncology at Southern Research

Rebecca BoohackerRebecca BoohackerBoohaker is the principal investigator of the oncology department. She designs, supervises, conducts and interprets all cancer-related in vivo Studies to evaluate potential cancer treatments, including cancer-fighting viruses and other agents that could help fight the disease. Boohaker is primarily trained as a molecular biologist, and her graduate work at the University of Central Florida led to a targeted peptide therapy to fight triple-negative breast cancer. Since joining Southern Research, her recent work has focused on chemoresistant colon cancers as well as pancreatic cancers, which are aggressive and highly resistant to treatment.

Boohaker received a bachelor's degree in biology from the University of Alabama at Birmingham and a doctorate in biomedical sciences from the University of Central Florida. Her postdoctoral work at Southern Research focused on cancer biology and DNA damage repair.

You may also like...